The last decade has witnessed significant progress in the use of GLP-1 Receptor antagonists. eg. Wegovy, Ozempic and Mounjaro in Type 2 diabetes and obesity. In obesity Ozempic is associated with 15% weight reduction and Mounjaro leads to 22% weight loss making it the most effective agent available in weight management. Recent data showed these agents have led to cardiovascular (CVD) and chronic kidney disease (CKD ) risk reduction (Ozempic); and improvement in sleep apnoea (Mounjaro).
These findings have led to the indications for using these agents being extended to the management of obesity, CVD and CKD with and without diabetes. When used appropriately, these agents are safe and well tolerated.
Abdul Lakhdar MSc FRCPG FRCP
Consultant Endocrinologist , The Frater Clinic
President, The Diabetes & Endocrine section of the Royal Society of Medicine
